Mono Thread RE Generative Medicine 27G/50mm 10 PCS.
N-Finders
PDO Thread
Mono Polydioxanone (PDO) Thread for Regenerative Medicine
Certifications
Certified by KFDA (Korea) as a Class IV medical device for regenerative medicine applications.
CE Marked in the European Union as a Class III medical device PDO thread system.
Manufactured under ISO and KGMP (Korean Good Manufacturing Practice) quality management systems.
PDO material tested in vitro and in vivo with documented biocompatibility, biodegradation and tissue Engineering scaffold properties according to manufacturer data.
Certified by KFDA (Korea) as a Class IV medical device for regenerative medicine applications.
CE Marked in the European Union as a Class III medical device PDO thread system.
Manufactured under ISO and KGMP (Korean Good Manufacturing Practice) quality management systems.
PDO material tested in vitro and in vivo with documented biocompatibility, biodegradation and tissue Engineering scaffold properties according to manufacturer data.
Mono Polydioxanone (PDO) Thread for Regenerative Medicine
Description
Mono Thread RE Generative Medicine 27G/50mm 10 PCS. is an absorbable monofilament polydioxanone (PDO) thread from N-Finders’ RE:Thread regenerative medicine line. Affixed to a fine 27G needle with a 50 mm PDO filament, it is used for minimally invasive lifting and skin rejuvenation procedures on the face and body. The RE:Thread system has passed strict clinical tests, is approved by KFDA and CE, and is designed to regenerate skin tissues, tighten lax areas, and refine contours with minimal downtime and no surgical incisions.
Bnefits
Absorbable polydioxanone (PDO) monofilament thread designed for regenerative medicine and skin tissue regeneration.
Certified by KFDA (Class IV) and CE (Class III) and manufactured under ISO and KGMP quality systems for safety and reliability.
Minimally invasive, non-surgical procedure with no incisions and no scarring, allowing short downtime and rapid recovery.
Improves cortical collagen loss, increases epidermal firmness and reduces fine lines and wrinkles.
Helps improve irregular skin texture and atrophic "bump holes" such as acne scarring.
Lifts and tightens sagging tissues to create more defined three-dimensional facial contours and a more youthful appearance.
Tightens double chin and neck area, smoothing fine lines and reducing neck sagging.
RE:Thread technology provides immediate lifting and tissue tightening, with neocollagenesis and neovascularisation for longer-term rejuvenation.
Demonstrated increases in growth factors (EGF, FGF, IGF, TGF, VEGF) and enhanced microcirculation in manufacturer studies.
Monofilament design reduces infection risk and minimises thread dimpling or puckering compared with older thread systems.
Indications
General skin tightening and fine wrinkle reduction on the face and body.
Improvement of cortical collagen loss and epidermal firmness.
Textural improvement of atrophic or irregular areas ("bump holes" such as acne scarring).
Mild to moderate lifting and contouring of mid-face and jawline.
Enhancing three-dimensional facial contours and restoring youthful appearance.
Tightening and contour refinement of double chin and submental area.
Outer carton / pouch labelled with N-Finders RE:Thread branding, size (27G/50mm) and lot / expiry information.
CE-marked medical device supplied for professional use in aesthetic and regenerative medicine settings.
Usage
For professional use only; insertion must be performed by appropriately trained and qualified medical practitioners familiar with PDO thread techniques and facial / body anatomy.
Assess patient indications, contraindications and expectations; obtain informed consent prior to treatment.
Cleanse and disinfect the treatment area with an appropriate antiseptic solution according to clinic protocol.
Mark insertion and exit points and planned vector directions on the skin where required.
Insert the 27G needle with preloaded PDO thread into the target tissue plane (typically the subdermal or deep dermal / subcutaneous layer, depending on indication and technique).
Advance the needle along the planned vector; once the needle reaches the desired end point, withdraw the needle while leaving the PDO thread in place.
Repeat with multiple threads to create a collagen-stimulating mesh or lifting pattern tailored to the treatment objective.
Avoid intravascular placement and high-risk anatomical structures; aspiration prior to insertion or between advances may be used according to practitioner preference and local guidelines.
Gently apply pressure or massage as needed to smooth the skin surface and minimise dimpling.
Instruct the patient to avoid vigorous manipulation of the treated area, high-impact exercise and extreme facial movements for several days according to clinic protocol.
Dispose of all used needles, packaging and any sharps in approved clinical sharps containers after a single use.
Contraindications
Known hypersensitivity or allergy to polydioxanone or any component of the device.
Active skin infection, inflammation, dermatitis, acne or herpetic lesions at or near the planned insertion sites.
Systemic infection or febrile illness at the time of treatment.
Uncontrolled diabetes mellitus or significant impairment of wound healing, unless carefully evaluated and managed by the treating physician.
Bleeding disorders or current use of strong anticoagulant or antiplatelet therapy where local haemostasis cannot be adequately controlled.
Autoimmune connective tissue diseases or immunosuppression where wound healing or foreign-body reactions may be unpredictable (relative contraindication; requires specialist judgement).
History of keloid or hypertrophic scar formation in areas to be treated.
Previous permanent threads, implants or fillers along the exact planned insertion path (relative contraindication requiring advanced expertise).
Pregnancy or breastfeeding, as safety of PDO thread lifting in these groups has not been established.
Unrealistic expectations or inability to comply with post-procedure care instructions.
Adverse Effects
Transient pain, tenderness or discomfort along the insertion path.
Erythema (redness), oedema (swelling) and bruising at needle entry and along thread trajectory.
Minor bleeding or haematoma formation at injection / insertion sites.
Temporary skin irregularities, dimpling or puckering, usually resolving as tissues relax and integrate around the thread.
Palpable or visible threads if placed too superficially, especially in thin or mobile areas.
Infection along the thread tract or at entry points (may require antibiotics or, rarely, thread removal).
Allergic or foreign-body type inflammatory reactions (rare).
Thread migration, extrusion or breakage (rare; more likely if insertion depth or aftercare is suboptimal).
Nerve irritation, dysesthesia or temporary sensory disturbance in the treated area (rare).
Vascular injury with local ischaemia or necrosis if a needle damages or enters a blood vessel (rare but serious).
Storage Conditions
Store in a clean, dry place at controlled room temperature, typically between 2 °C and 25 °C, as per standard PDO suture / medical device storage recommendations.
Keep away from direct sunlight, excessive heat and high humidity.
Maintain the product in its original sterile blister and outer packaging until immediately before use.
Do not use if the sterile barrier is damaged or opened, or if the product is past the labelled expiry date.
Single-use only – do not resterilise or reuse any needle or thread.
Dispose of opened, unused or expired products in accordance with local regulations for medical devices and sharps.
Duration
PDO thread itself biodegrades over approximately 6\u20138 months, while the collagen remodelling and lifting / tightening effects generally persist beyond biodegradation, often up to around 12\u201318 months depending on treatment area, number of threads used, technique and individual patient factors.
Onset
Immediate mechanical lifting and tissue tightening after thread placement, with progressive improvement in skin quality and firmness over subsequent weeks and months as neocollagenesis and neovascularisation occur.
